Annual Report

The report describes Dr. Reddy's 2007-08 consolidation, with consolidated revenue falling 23% to Rs. 50,006 million. Branded-formulations revenue grew 16%, and the company launched Reditux, a monoclonal antibody biosimilar. Environmental actions included commissioning another zero-liquid-discharge plant and installing scrubbers to reduce fugitive emissions.